WHAT IS CLAIMED IS:

1. Use of a first amount of capivasertib or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a B-cell malignancy in a patient in need thereof, wherein the first amount of capivasertib or a pharmaceutically acceptable salt thereof is to be administered to the patient in combination with a second amount of venetoclax or a pharmaceutically acceptable salt thereof; wherein the first amount and second amount together comprise a therapeutically effective amount.

2. Use of a second amount of venetoclax or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a B-cell malignancy in a patient in need thereof, wherein the second amount of venetoclax or a pharmaceutically acceptable salt thereof is to be administered to the patient in combination with a first amount of capivasertib or a pharmaceutically acceptable salt thereof; wherein the first amount and second amount together comprise a therapeutically effective amount.

3. The use of claim 1 or 2, wherein the B-cell malignancy is diffuse large B-cell lymphoma (DLBCL), germinal center B-cell-like diffuse large B-cell lymphoma (GCB-DLBCL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or follicular lymphoma.

4. The use of claim 3, wherein the B-cell malignancy is germinal center B-cell-like diffuse large B-cell lymphoma (GCB-DLBCL).

5. The use of any one of claims 1 to 4, wherein the B-cell malignancy is PTEN-null.

6. The use of any one of claims 1 to 4, wherein venetoclax is dosed at least two hours after capivasertib is dosed, on days when both are dosed.

7. The use of any one of claims 1 to 6, wherein capivasertib is dosed on four days in a seven-day dosage cycle.

8. The use of any one of claims 1 to 6, wherein capivasertib is to be administered at a dose of 300 to 800 mg twice daily, optionally about 320 mg, about 400 mg or about 480 mg twice daily, on days one, two, three and four of a seven-day dosage cycle.

9. The use of any one of claims 1 to 6, wherein capivasertib is dosed on two days in a seven-day dosage cycle.

10. The use of any one of claims 1 to 6, wherein capivasertib is to be administered at a dose of 300 to 800 mg twice daily, optionally about 480 mg, about 560 mg or about 640 mg twice daily, on days one and two of a seven-day dosage cycle.

11. The use of any one of claims 1 to 10, wherein capivasertib is dosed for three weeks and not dosed during week four.

12. The use of any one of claims 1 to 11, wherein venetoclax is dosed on seven days in a seven-day dosage cycle.

13. The use of any one of claims 1 to 11, wherein venetoclax is dosed one, two, three, four, five, or six days in a seven-day dosage cycle.

14. The use of any one of claims 1 to 11, wherein venetoclax is dosed four days in a seven-day dosage cycle.

15. The use of any one of claims 1 to 11, wherein venetoclax is dosed three days in a seven-day dosage cycle.

16. The use of any one of claims 1 to 11, wherein venetoclax is dosed two days in a seven-day dosage cycle.

17. The use of any one of claims 1 to 11, wherein venetoclax is dosed one day in a seven-day dosage cycle.

18. The use of any one of claims 1 to 11, wherein venetoclax is dosed only on day(s) when capivasertib is dosed.

19. The use of any one of claims 1 to 6 and 11, wherein capivasertib is dosed on two days or four days of a seven-day dosage cycle, and venetoclax is dosed on one, two, three, four, five, six, or seven days of a seven-day dosage cycle.

20. The use of claims 19, wherein venetoclax is dosed on one, two, four, or seven days of a seven-day dosage cycle.

21. Use of capivasertib or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a B-cell malignancy in a patient in need thereof, wherein capivasertib or a pharmaceutically acceptable salt thereof is to be administered to the patient in combination with venetoclax or a pharmaceutically acceptable salt thereof, wherein:

in a seven-day dosage cycle:

a first amount of capivasertib or a pharmaceutically acceptable salt thereof on two days or on four days, and

a second amount of venetoclax or a pharmaceutically acceptable salt thereof on seven days,

are to be administered to the patient; and

in a later seven-day dosage cycle:

a first amount of capivasertib or a pharmaceutically acceptable salt thereof on two days or on four days, and

a second amount of venetoclax or a pharmaceutically acceptable salt thereof on one, two, three, four, five or six days,

are to be administered to the patient;

wherein the first amount and second amount together comprise a therapeutically effective amount.

22. Use of venetoclax or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a B-cell malignancy in a patient in need thereof, wherein venetoclax or a pharmaceutically acceptable salt thereof is to be administered to the patient in combination with capivasertib or a pharmaceutically acceptable salt thereof, wherein:

in a seven-day dosage cycle:

a first amount of capivasertib or a pharmaceutically acceptable salt thereof on two days or on four days, and

a second amount of venetoclax or a pharmaceutically acceptable salt thereof on seven days,

are to be administered to the patient; and

in a later seven-day dosage cycle:

a first amount of capivasertib or a pharmaceutically acceptable salt thereof on two days or on four days, and

a second amount of venetoclax or a pharmaceutically acceptable salt thereof on one, two, three, four, five or six days,

are to be administered to the patient;

wherein the first amount and second amount together comprise a therapeutically effective amount.

23. The use of claim 21 or 22, wherein capivasertib is dosed on days one, two, three and four of a seven-day dosage cycle, and venetoclax is dosed on day one, and on an additional one, two, or three days of the seven-day dosage cycle.

24. The use of claim 21 or 22, wherein capivasertib is dosed on days one and two of a seven-day dosage cycle, and venetoclax is dosed on day one, and on an additional one, two, or three days of the seven-day dosage cycle.

25. The use of any one of claims 22 to 24, wherein venetoclax is dosed on day one and either day two or day three of the seven-day dosage cycle.

26. Use of capivasertib or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a B-cell malignancy in a patient in need thereof, wherein capivasertib or a pharmaceutically acceptable salt thereof is to be administered to the patient in combination with venetoclax or a pharmaceutically acceptable salt thereof, wherein:

in a seven-day dosage cycle:

a first amount of capivasertib or a pharmaceutically acceptable salt thereof on two days or four days, and

a second amount of venetoclax or a pharmaceutically acceptable salt thereof on seven days,

are to be administered to the patient; and

in a later seven-day dosage cycle:

a first amount of capivasertib or a pharmaceutically acceptable salt thereof on two days or four days, and

a third amount of venetoclax or a pharmaceutically acceptable salt thereof on seven days, wherein the third amount is less than the second amount,

are to be administered to the patient;

wherein the first amount and second amount together comprise a therapeutically effective amount, and wherein the first amount and third amount together comprise a therapeutically effective amount.

27. Use of venetoclax or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a B-cell malignancy in a patient in need thereof, wherein venetoclax or a pharmaceutically acceptable salt thereof is to be administered to the patient in combination with capivasertib or a pharmaceutically acceptable salt thereof, wherein:

in a seven-day dosage cycle:

a first amount of capivasertib or a pharmaceutically acceptable salt thereof on two days or four days, and

a second amount of venetoclax or a pharmaceutically acceptable salt thereof on seven days,

are to be administered to the patient; and

in a later seven-day dosage cycle:

a first amount of capivasertib or a pharmaceutically acceptable salt thereof on two days or four days, and

a third amount of venetoclax or a pharmaceutically acceptable salt thereof on seven days, wherein the third amount is less than the second amount,

are to be administered to the patient;

wherein the first amount and second amount together comprise a therapeutically effective amount, and wherein the first amount and third amount together comprise a therapeutically effective amount.

28. Use of capivasertib or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a B-cell malignancy in a patient in need thereof, wherein capivasertib or a pharmaceutically acceptable salt thereof is to be administered to the patient in combination with venetoclax or a pharmaceutically acceptable salt thereof, wherein:

in a seven-day dosage cycle:

from 300 to 800 mg of capivasertib twice daily on days one, two, and optionally days three and four, and

from 20 to 400 mg of venetoclax once daily on seven days,

are to be administered to the patient; and

in a later seven-day dosage cycle:

from 300 to 800 mg of capivasertib twice daily on days one, two, and optionally days three and four of the later seven-day dosage cycle, and

from 20 to 400 mg of venetoclax once daily on day one and on an additional one, two, or three days of the later seven-day dosage cycle,

are to be administered to the patient.

29. Use of venetoclax or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a B-cell malignancy in a patient in need thereof,

wherein venetoclax or a pharmaceutically acceptable salt thereof is to be administered to the patient in combination with capivasertib or a pharmaceutically acceptable salt thereof, wherein:

in a seven-day dosage cycle:

from 300 to 800 mg of capivasertib twice daily on days one, two, and optionally days three and four, and

from 20 to 400 mg of venetoclax once daily on seven days,

are to be administered to the patient; and

in a later seven-day dosage cycle:

from 300 to 800 mg of capivasertib twice daily on days one, two, and optionally days three and four of the later seven-day dosage cycle, and

from 20 to 400 mg of venetoclax once daily on day one and on an additional one, two, or three days of the later seven-day dosage cycle,

are to be administered to the patient.

30. Capivasertib for use in treating a B-cell malignancy.

31. Venetoclax for use in treating a B-cell malignancy.

32. A kit comprising (i) capivasertib, and (ii) instructions for the use of capivasertib in the use of any one of claims 1-29.

33. The use of any one of claims 1-29, wherein a combination of capivasertib and venetoclax is to be administered to the patient, wherein the combination is for the simultaneous, separate, or sequential dosing of capivasertib and venetoclax.

34. The use of any one of claims 1-29, wherein a combination of capivasertib and venetoclax is to be administered to the patient, the combination comprising: a first amount of capivasertib or a pharmaceutically acceptable salt thereof, and a second amount of venetoclax or a pharmaceutically acceptable salt thereof; wherein the first amount and second amount together comprise a therapeutically effective amount; wherein the combination is for the simultaneous, separate, or sequential dosing of capivasertib and venetoclax.

35. The use of claim 33 or 34, wherein the combination is for separate or sequential dosing.